SCHEMBL516008

SCHEMBL516008

O=C1C=CC2(CCCC2)CC1

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL515788 0.98 ALDH1A1 (0.34) ALDH1A1ALOX5
SCHEMBL9449773 0.98 ALDH1A1 (0.34) ALDH1A1ALOX5
SCHEMBL1373549 0.98 ALDH1A1 (0.34) ALDH1A1ALOX5
SCHEMBL13333805 0.95 ALDH1A1 (0.36) ALDH1A1ALOX5
SCHEMBL9140299 0.90
SCHEMBL17277743 0.80 NEK2 (0.31)
SCHEMBL3728133 0.80
SCHEMBL4409815 0.79 ALDH1A1 (0.34) ALDH1A1ALOX5
SCHEMBL11956609 0.77 ALOX5 (0.30) ALOX5
SCHEMBL12087982 0.77 HTR2A (0.37) ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230301970-A1 CARBOXAMIDE DERIVATIVES NOVARTIS PHARMACEUTICALS UK LIMITED (GB) 2023-09-28 US disclosed
US-11672782-B2 Carboxamide derivatives NOVARTIS AG (CH) 2023-06-13 US disclosed
EP-3143018-B1 CARBOXAMIDE DERIVATIVES NOVARTIS AG (CH) 2021-03-10 EP disclosed
US-20210052554-A1 CARBOXAMIDE DERIVATIVES NOVARTIS PHARMACEUTICALS UK LIMITED (GB) 2021-02-25 US disclosed
US-20200268718-A1 CARBOXAMIDE DERIVATIVES NOVARTIS AG (CH) 2020-08-27 US disclosed
US-10195181-B2 Carboxamide derivatives NOVARTIS AG (CH) 2019-02-05 US disclosed
EP-3143018-A1 CARBOXAMIDE DERIVATIVES Novartis AG (CH) 2017-03-22 EP disclosed
US-20170014388-A1 CARBOXAMIDE DERIVATIVES NOVARTIS AG (CH) 2017-01-19 US disclosed
EP-1698620-B1 BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS EISAI R&D MAN CO LTD (JP) 2016-09-28 EP disclosed
EP-1698620-B1 BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS EISAI R&D MAN CO LTD (JP) 2016-09-28 EP disclosed
US-7410971-B2 1,2-di(cyclic)substituted benzene compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-08-12 US disclosed
US-20080176926-A1 G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease ACTELION PHARMACEUTICALS LTD. (CH) 2008-07-24 US disclosed
EP-1863787-A1 HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS Actelion Pharmaceuticals Ltd. (CH) 2007-12-12 EP disclosed
US-20070112002-A1 1,2-di(cyclic)substituted benzene compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-17 US disclosed
US-20070112002-A1 1,2-di(cyclic)substituted benzene compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-17 US disclosed
US-20070112002-A1 1,2-di(cyclic)substituted benzene compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-17 US disclosed
US-20060276465-A1 1,2-di(cyclic) substituted benzene compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-12-07 US disclosed
WO-2006100631-A1 HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2006-09-28 WO disclosed
EP-1698620-A1 BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS Eisai Co., Ltd. (JP) 2006-09-06 EP disclosed
US-20050261291-A1 1,2-Di(cyclic)substituted benzene compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052554-A1 CARBOXAMIDE DERIVATIVES SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885ALOX5 1468/4885
US-20230301970-A1 CARBOXAMIDE DERIVATIVES SIRT1, ADCY5, ASIC1 ALDH1A1 183/4885ALOX5 1713/4885
US-20070112002-A1 1,2-di(cyclic)substituted benzene compounds CCR10, HRH3, HRH1 ALDH1A1 707/4885ALOX5 490/4885
US-11672782-B2 Carboxamide derivatives SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885ALOX5 1468/4885
US-20200268718-A1 CARBOXAMIDE DERIVATIVES SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885ALOX5 1468/4885
US-20170014388-A1 CARBOXAMIDE DERIVATIVES SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885ALOX5 1468/4885
US-20080176926-A1 G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease S1PR1, S1PR3, S1PR5 ALDH1A1 1893/4885ALOX5 1862/4885
US-20050261291-A1 1,2-Di(cyclic)substituted benzene compounds CCR10, HRH3, HRH2 ALDH1A1 705/4885ALOX5 266/4885
US-20060276465-A1 1,2-di(cyclic) substituted benzene compounds HRH3, CCR10, HRH1 ALDH1A1 617/4885ALOX5 744/4885
US-10195181-B2 Carboxamide derivatives SIRT5, SIRT7, ADCY5 ALDH1A1 350/4885ALOX5 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.